Pharmacogenomics News and Research

RSS

The terms pharmacogenomics and pharmacogenetics are often used interchangeably to describe a field of research focused on how genes affect individual responses to medicines. Whether a medicine works well for you—or whether it causes serious side effects—depends, to a certain extent, on your genes.

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

To help advance research on how genes affect responses to medicines, the National Institutes of Health is spending $15 million over five years to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB), http://www.pharmgkb.org/ .

8 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

8 Sep 2010

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children.

8 Sep 2010

Penn receives $12M NIH grant to study pharmacogenetics of nicotine addiction treatment

A variety of smoking cessation treatments are currently available for the more than 18 million adult Americans try to quit smoking each year, but success rates vary widely. Despite the importance of quitting smoking, more personalized approaches to smoking cessation treatment are needed to help smokers pick the right method that will work best for them. A major new personalized medicine clinical trial, led by addiction researchers at the University of Pennsylvania, will study how a smokers' genetic make-up influences their quitting success.

8 Sep 2010

UCSF scientists to receive two grants for personalized medicine research

UCSF scientists will receive two grants totaling $15.1 million over the next five years to expand their research into how genes affect an individual's response to medication and to strengthen a global network of researchers involved in these efforts.

7 Sep 2010

ECRI Institute's 17th Annual Conference to be held October 19-20, at NIH

With the advent of healthcare reform, the United States is embarking on an unprecedented effort to determine which health care intervention works best for the diagnosis or treatment of a given disease or condition. While comparative effectiveness and personalized medicine evolved separately, these significant trends interface, increasingly, in the healthcare systems.

3 Sep 2010

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced today that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory.

2 Sep 2010

Clearstone Central Laboratories announces strategic global collaboration with LabCorp

Clearstone Central Laboratories, a leading provider of central laboratory services for late-stage clinical trials, announced today a global collaboration with Laboratory Corporation of America® Holdings through its Esoterix Clinical Trials Services division, providing clients with seamless access to CAP-accredited laboratories across both organizations in Belgium, Canada, China, France, Singapore and the United States.

13 Aug 2010

Transgenomic second-quarter net loss increases to $1.1 million

Transgenomic, Inc. today reported financial results for the three and six months ended June 30, 2010, and provided a business update.

13 Aug 2010

New insights into development and applications of pharmacogenomics in psychiatry

In recent years, there have been major developments in the fields of pharmacogenetics and pharmacogenomics, with the potential to make drug treatments in psychiatric medicine more effective. However, improvements in drug efficacy and tolerability, as well as finding the optimal dosage, can only be realized if in vivo mechanisms of drug action and ADME (absorption, distribution, metabolism, excretion) processes (pharmacokinetics) of psychopharmacological agents are better understood.

5 Aug 2010

QPS acquires Xendo Drug Development

QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen, The Netherlands. XDD, a European contract research organization (CRO), will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC.

26 Jul 2010

NIH awards $2.8M grant for development of diagnostic multiplex testing platform with BMB technology

Applied BioCode, Inc. and Maxwell Sensors Inc. announced today that they have received a $2.8M three-year grant from the Recovery Act Limited Competition: National Institutes of Health (NIH), for the development of a high throughput diagnostic multiplex testing platform using their Barcoded Magnetic Beads (BMB) technology for various high value immunodiagnostics and molecular diagnostic tests.

7 Jul 2010

Gen-Probe invests $50M in Pacific Biosciences

Gen-Probe Incorporated and Pacific Biosciences announced today that Gen-Probe has made a $50 million strategic investment in Pacific Biosciences, a private sequencing company. In addition, the companies will work together to explore co-development of new integrated clinical diagnostics systems based on Pacific Biosciences' Single Molecule Real Time (SMRT™) platform and Gen-Probe's expertise in diagnostics.

18 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

At the 2nd Annual Consumer Genetics Conference taking place in Boston from June 2-4 at the Hynes Convention Center, these issues will be addressed and preeminent leaders from varying areas of expertise will provide perspectives on these crucial topics that are shaping the way we approach clinical medicine and helping to improve patient outcomes.

29 May 2010

WaferGen Biosystems first-quarter revenues increase to $389,785

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.

17 May 2010

ACM Global renews CAP accreditation for the third time

ACM Global Central Laboratory, the global central lab that continually defines the customer-service standard with its flexible approach, has renewed its College of American Pathologists accreditation for the third time based on the results of a recent onsite inspection.

17 May 2010

SNP biomarker could reduce guesswork associated with prescribing drugs

A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.

11 May 2010

Iris Biotechnologies receives two new Canadian patents

Iris BioTechnologies Inc., a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, today announced two new Canadian patents.

11 May 2010

Pharmacogenomics News and Research

Further Reading

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

Penn receives $12M NIH grant to study pharmacogenetics of nicotine addiction treatment

UCSF scientists to receive two grants for personalized medicine research

ECRI Institute's 17th Annual Conference to be held October 19-20, at NIH

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Clearstone Central Laboratories announces strategic global collaboration with LabCorp

Transgenomic second-quarter net loss increases to $1.1 million

New insights into development and applications of pharmacogenomics in psychiatry

QPS acquires Xendo Drug Development

NIH awards $2.8M grant for development of diagnostic multiplex testing platform with BMB technology

Gen-Probe invests $50M in Pacific Biosciences

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

WaferGen Biosystems first-quarter revenues increase to $389,785

ACM Global renews CAP accreditation for the third time

SNP biomarker could reduce guesswork associated with prescribing drugs

Iris Biotechnologies receives two new Canadian patents

Genetics & Genomics - Second Edition eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News